• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Little guidance provided for second- step antidepressant selection

Little guidance provided for second- step antidepressant selection

October 1, 2008
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Section editor, Glen Spielmans, PhD

The most recent findings from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial provided little help regarding which medication to prescribe if an initial SSRI trial failed to result in remission of depressive symptoms. Patients who did not show remission after a Celexa (citalopram) trial were assigned to receive Wellbutrin (bupropion), Zoloft (sertraline), or Effexor (venlafaxine). Very few patient characteristics or first-step treatment features were reliably linked to differential response to any of the medica- tions. Patientswithcomorbidgeneralized anxiety, OCD, panic disorder, PTSD, or social phobia were all less likely (some- times to a statistically significant extent) to remit in the second step regardless of the specific medication they received. Anxious features correlated with lower remission rates across all medications. Effexor was associated with a lower chance of remis- sion among patients with a comorbid substance abuse disorder, but given the large number of statistical tests run by the researchers, this could be a chance finding. Unsurprisingly, patients who could not tolerate Celexa in the first step were less likely to tolerate Zoloft (another SSRI) in the second step, compared to Wellbutrin or Effexor (Rush AJ et al., Arch Gen Psychiatry. 2008;65:870-881).

TCPR'S Take: In the second step of treatment, remission rates were relatively low across all medications, ranging from 18%-27% depending on the depression measure. Thesefindingsprovidelittle helpful information for prescribers regard- ing medication selection for depression that is not completely responsive to first- steptreatment. TheJanuary2007issueof TCPR offers additional advice regarding treatment-resistant depression.

General Psychiatry
KEYWORDS antidepressants
    www.thecarlatreport.com
    Issue Date: October 1, 2008
    SUBSCRIBE NOW
    Table Of Contents
    Using Treatment Guidelines
    Outcome Scales in Psychiatry
    Using the PHQ-9 in Psychiatric Practice
    Little guidance provided for second- step antidepressant selection
    Viagra reduces SSRI-induced sexual side effects in women
    Psychiatrists providing less psychotherapy
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.